Abstract:Objective To investigate the molecular epidemiology and mechanism of earbapenem resistance of Serratia marcescens,Klebsiella pneumoniae and Escherichia coli isolates from intensive care units(ICUs).Methods Twenty-one S.marcescens,ten K.pneumoniae and one E.coli isolates with carbapenem resistance or reduced carbapenem susceptibility were recovered from two ICUs in our hospital from April 2006 to Febmary 2007.Pulsed-field gel electrophoresis(PFGE)and enterobacterial repetitive intergenic consensus-PCR(ERIC-PCR)were performed to analyze the molecular epidemiology of isolates.Antibiotic susceptibilities were determined bv agar dilution method.Conjugation experiments were carried out in mixed broth cultures.Plasmid DNA was obtained bv using an alkalinelysis technique and was digested by various endonucleases.Elimination of plasmid from S.marcesceus isolates were performed by repeated SDS treatment.The crude β-lactamase extracts of original isolates and E.coli transconjugants were subjected to isoelectric focusing(IEF);Specific PCRs and DNA sequencing were preformed to confirm the genotype of β-lactamases.Results ERIC-PCR indicated that all S.marcescens isolates belonged to a clonal strain.PFGE indicated that ten K. pneumoniae isolates were indistinguishable or closely related to each other.The MICs of imipenem and meropenero for all isolates were 2 to 8 μg/ml except K.pneumoniae K10(128 and 256 μg/ml).Conjugation studies with E.coli(EC600)resulted in the transfer of reduced carbapenem susceptibility from original isolates(MICs:from≤0.125 μg/ml to 1-2μg/ml).IEF,PCR and DNA sequence analysis confirmed that S.marcescens isolates produced KPC-2(pI of 6.7)and a β-lactamase(pI 6.5).k pneumoniae isolates produced TEM-1(pI 5.4),KPC-2,CTX-M-14(pI 7.9),and a β-lactamase(pI 7.3).E.coli El produced KPC-2,CTX-M-15(pI 9.0),and a β-laetamase(pI 7.3).Only a KPC-2 was detected in E.coli transeonjugants.Plasmid restricfion analysis using EcoR Ⅰ,Hind Ⅲ,and Bcu Ⅰ showed identical restrietion patterns among all E.coli transconjugants.SDS-PAGE and ompK 35/36 gene sequence analysis of OMPs revealed that K.pneumoniae K10 failed to express OmpK36 because of insertional inactivation by an insertion of ISEcp1.Conclusions Carbapenem-non-susceptible S.marcescens.K.pneumoniae and E.coli were epidemic in two ICUs in our hospital.Resistance or reduced susceptibility to carbapenems in these strains is mainly due to production of KPC-2.Presence of KPC-2 combined with porin deftciency result in high-level carbaoenem resistance in K.pneumoniae.The game blaKPC2-encoding plasmid spreads among the three different genera.

Doripenem, Gentamicin, and Colistin, Alone and in Combinations, Against Gentamicin-Susceptible, Kpc-Producing Klebsiella Pneumoniae Strains with Various Ompk36 Genotypes

Efficacy of synergistic antibiotic combinations against KPC-2 carbapenemase producing Klebsiella pneumoniae strains

Mutations of the Ompk36 Porin Gene and Promoter Impact Responses of Sequence Type 258, KPC-2-Producing Klebsiella Pneumoniae Strains to Doripenem and Doripenem-Colistin

Reduced carbapenem susceptibility in Klebsiella pneumoniae clinical isolates is due to combination of β-lactamases and the loss of OmpK36 porin

Doripenem MICs and Ompk36 Porin Genotypes of Sequence Type 258, KPC-producing Klebsiella Pneumoniae May Predict Responses to Carbapenem-Colistin Combination Therapy among Patients with Bacteremia.

In Vivo Emergence Of Colistin Resistance In Carbapenem-Resistant Klebsiella Pneumoniae Mediated By Premature Termination Of The Mgrb Gene Regulator

Reduced Susceptibility to Carbapenems in Klebsiella Pneumoniae Clinical Isolates Associated with Plasmid-Mediated Beta-Lactamase Production and OmpK36 Porin Deficiency.

Characterization of Porin Expression in Klebsiella Pneumoniae Carbapenemase (Kpc)-Producing K. Pneumoniae Identifies Isolates Most Susceptible to the Combination of Colistin and Carbapenems.

The presence of high-level carbapenem resistance in Klebsiella pneumoniae is due to the combination of IMP-4 metallo-β-lactamase and porin OmpK36 deficiency

In vitro Pharmacokinetics/Pharmacodynamics Evaluation of Fosfomycin Combined with Amikacin or Colistin against KPC2-Producing Klebsiella pneumoniae.

Study of In Vitro Synergistic Bactericidal Activity of Dual β-Lactam Antibiotics Against KPC-2-Producing Klebsiella pneumoniae .

Insight into Antibiotic Synergy Combinations for Eliminating Colistin Heteroresistant Klebsiella pneumoniae

Impact of porin deficiency on the synergistic potential of colistin in combination with β-lactam/β-lactamase inhibitors against ESBL- and carbapenemase-producing Klebsiella pneumoniae

<i>In vitro</i> Synergistic Activity of Antimicrobial Combinations Against <i>bla</i><sub>KPC</sub> and <i>bla</i><sub>NDM</sub>-Producing <i>Enterobacterales</i> With <i>bla</i><sub>IMP</sub> or mcr Genes

Optimal Empiric Treatment for KPC-2-producing Klebsiella Pneumoniae Infections in Critically Ill Patients with Normal or Decreased Renal Function Using Monte Carlo Simulation

In Vitro Antibacterial Effect of Fosfomycin Combination Therapy Against Colistin-Resistant Klebsiella Pneumoniae

Identification of Plasmid-Mediated Carbapenem-Hydrolyzing Β-Lactamase KPC-2 in Enterobacteriaceae

Efficacy of colistin alone and in various combinations for the treatment of experimental osteomyelitis due to carbapenemase-producing Klebsiella pneumoniae

Antagonistic Effect Between Tigecycline and Meropenem: Successful Management of KPC-producing Klebsiella Pneumoniae Infection

In Vitro Activity of Minocycline Combined with Aminoglycosides Against Klebsiella Pneumoniae Carbapenemase-Producing K. Pneumoniae

bla KPC and rmtB on a single plasmid in Enterobacter amnigenus and Klebsiella pneumoniae isolates from the same patient